Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

GENEVANT SCIENCES, INC. — Lobbying — Receipts Report

LD-2 disclosure · 2nd Quarter - Amendment

GENEVANT SCIENCES, INC.

via NOVEL STRATEGIES (FKA) PRISM GROUP

2nd Quarter (Apr 1 - June 30) · 2023Posted Jan 5, 2024Filing document ↗LDA record ↗

Income$40Kfee reported

Client

Name: GENEVANT SCIENCES, INC.
Description: Business/legal/admin.for tech-focused nucleic acid development and delivery company
Location: Massachusetts · United States of America

Registrant

Firm: NOVEL STRATEGIES (FKA) PRISM GROUP
Description: A public affairs and government relations firm.
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
Healthcare matters
LobbyistsJOHN STANFORD · JAY BRETT PERRON
Covered position (JOHN STANFORD): n/a
Covered position (JAY BRETT PERRON): n/a
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.